{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:18Z","timestamp":1793323338314,"version":"4.5.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11914-025-00919-0","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:58:19Z","timestamp":1748872699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of Osteoporosis in Patients with Chronic Kidney Disease"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-8330","authenticated-orcid":false,"given":"Micha\u00ebl R.","family":"Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-2791","authenticated-orcid":false,"given":"Jolan","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-3240","authenticated-orcid":false,"given":"Wim","family":"Lemahieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Jamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bea","family":"Mellaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7289-1397","authenticated-orcid":false,"given":"Marian","family":"Dejaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-1201","authenticated-orcid":false,"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-4321","authenticated-orcid":false,"given":"Pieter","family":"Evenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1152\/physrev.00033.2015","volume":"97","author":"M Almeida","year":"2017","unstructured":"Almeida M, Laurent MR, Dubois V, Claessens F, O\u2019Brien CA, Bouillon R, et al. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev. 2017;97:135\u201387.","journal-title":"Physiol Rev"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11657-016-0258-3","volume":"11","author":"F Malgo","year":"2016","unstructured":"Malgo F, Appelman-Dijkstra NM, Termaat MF, van der Heide HJL, Schipper IB, Rabelink TJ, et al. High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD. Arch Osteoporos. 2016;11:12.","journal-title":"Arch Osteoporos"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00198-019-05187-0","volume":"31","author":"TT Jansz","year":"2020","unstructured":"Jansz TT, Goto NA, van Ballegooijen AJ, Willems HC, Verhaar MC, van Jaarsveld BC. The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2020;31:515\u201324.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4103\/sjmms.sjmms_639_21","volume":"10","author":"MM Mahzari","year":"2022","unstructured":"Mahzari MM, Alibrahim AR, Alghamdi NA, Alsadhan MA, Almoamary SM, Masuadi EM, et al. Prevalence and Risk Factors of Osteoporosis in Saudi End-Stage Renal Disease Patients on Hemodialysis. Saudi J Med Med Sci. 2022;10:259\u201365.","journal-title":"Saudi J Med Med Sci"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12882-025-03963-1","volume":"26","author":"X Hu","year":"2025","unstructured":"Hu X, Ye X, Chen H, Wu B, Guo Q, Yu C, et al. Depression as a risk factor for osteoporosis independent of sarcopenia in hemodialysis patients: findings from a multicenter cross-sectional study. BMC Nephrol. 2025;26:35.","journal-title":"BMC Nephrol"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.ajkd.2020.02.450","volume":"76","author":"T Vilaca","year":"2020","unstructured":"Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E, et al. Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a\u2013G5D: A Systematic Review and Meta-analysis. Am J Kidney Dis Off J Natl Kidney Found. 2020;76:521\u201332.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12882-020-02224-7","volume":"22","author":"L Xie","year":"2021","unstructured":"Xie L, Hu X, Li W, Ouyang Z. A retrospective study of end-stage kidney disease patients on maintenance hemodialysis with renal osteodystrophy-associated fragility fractures. BMC Nephrol. 2021;22:23.","journal-title":"BMC Nephrol"},{"key":"919_CR8","doi-asserted-by":"crossref","unstructured":"Jang YS, Kim H, Kim SY, Park YS, Yun I, Park E-C, et al. Effect of chronic kidney disease on all-cause mortality after hip fracture surgery: A retrospective cohort study. Calcif Tissue Int. 2024;","DOI":"10.1007\/s00223-024-01238-9"},{"key":"919_CR9","doi-asserted-by":"crossref","unstructured":"Hansen D, J\u00f8rgensen HS, Andersen TL, Ferreira AC, Ferreira A, de Jongh R, et al. Multidisciplinary team approach for CKD-associated osteoporosis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2024;gfae197.","DOI":"10.1093\/ndt\/gfae197"},{"key":"919_CR10","first-page":"313","volume":"11","author":"C-T Hsu","year":"2023","unstructured":"Hsu C-T, Deng Y-L, Chung M-C, Tsai S-F, Lin S-Y, Chen C-H. Integrated Osteoporosis Care to Reduce Denosumab-Associated Hypocalcemia for Patients with Advanced Chronic Kidney Disease and End-Stage Renal Disease. Healthc Basel Switz. 2023;11:313.","journal-title":"Healthc Basel Switz"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00198-020-05512-y","volume":"31","author":"L Van Camp","year":"2020","unstructured":"Van Camp L, Dejaeger M, Tournoy J, Gielen E, Laurent MR. Association of orthogeriatric care models with evaluation and treatment of osteoporosis: a systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2020;31:2083\u201392.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.nefro.2023.05.002","volume":"44","author":"J Bover","year":"2024","unstructured":"Bover J, G\u00f3mez-Alonso C, Casado E, Rodr\u00edguez-Garc\u00eda M, Lloret MJ, Castro-Alonso C, et al. Osteoporosis management in patients with chronic kidney disease (ERCOS Study): A challenge in nephrological care. Nefrologia. 2024;44:241\u201350.","journal-title":"Nefrologia"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s11914-018-0491-3","volume":"16","author":"P Khairallah","year":"2018","unstructured":"Khairallah P, Nickolas TL. Updates in CKD-Associated Osteoporosis. Curr Osteoporos Rep. 2018;16:712\u201323.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria B-H, Cheung AM, Chines AA, Gielen E, et al. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37:1437\u201345.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR15","doi-asserted-by":"crossref","unstructured":"Hara T, Hijikata Y, Matsubara Y, Watanabe N. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3\u20135D. Cochrane Database Syst Rev. 2021;7:CD013424.","DOI":"10.1002\/14651858.CD013424.pub2"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","volume":"33","author":"CW Fixen","year":"2022","unstructured":"Fixen CW, Fixen DR. Renal safety of zoledronic acid for osteoporosis in adults 75 years and older. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2022;33:2417\u201322.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR17","first-page":"581","volume":"49","author":"T Sabaghian","year":"2024","unstructured":"Sabaghian T, Delkash P, Rahmannia M, Shahidi Bonjar AH, Centis R, D\u2019Ambrosio L, et al. Efficacy and safety of anti-osteoporotic agents across CKD Stages: A meta-analysis of randomized clinical trials. Kidney Blood Press Res. 2024;49:581\u20137.","journal-title":"Kidney Blood Press Res"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jbmr.4235","volume":"36","author":"DE Robinson","year":"2021","unstructured":"Robinson DE, Ali MS, Pallares N, Teb\u00e9 C, Elhussein L, Abrahamsen B, et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: A binational cohort analysis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2021;36:820\u201332.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/jbmr.4573","volume":"37","author":"T Oda","year":"2022","unstructured":"Oda T, J\u00f6dicke AM, Robinson DE, Delmestri A, Keogh RH, Prieto-Alhambra D. Oral bisphosphonates are associated with increased risk of severe acute kidney injury in elderly patients with complex health needs: A self-controlled case series in the United Kingdom. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37:1270\u20138.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jbmr\/zjae070","volume":"39","author":"C Park","year":"2024","unstructured":"Park C, Kim C, Park RW, Jeon JY. Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea. J Bone Miner Res Off J Am Soc Bone Miner Res. 2024;39:835\u201343.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR21","first-page":"42","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust M-H, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2021;36:42\u201359.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"173","key":"919_CR22","first-page":"299","volume":"2023","author":"D Cejka","year":"1946","unstructured":"Cejka D, Wakolbinger-Habel R, Zitt E, Fahrleitner-Pammer A, Amrein K, Dimai HP, et al. Diagnosis and treatment of osteoporosis in patients with chronic kidney disease\u202f: Joint guidelines of the Austrian Society for Bone and Mineral Research (\u00d6GKM), the Austrian Society of Physical and Rehabilitation Medicine (\u00d6GPMR) and the Austrian Society of Nephrology (\u00d6GN). Wien Med Wochenschr. 1946;2023(173):299\u2013318.","journal-title":"Wien Med Wochenschr"},{"key":"919_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/postgradmedj-2021-140341","volume":"99","author":"C-C Kao","year":"2023","unstructured":"Kao C-C, Wu P-C, Chuang M-T, Yeh S-C, Lin Y-C, Chen H-H, et al. Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease. Postgrad Med J. 2023;99:340\u20139.","journal-title":"Postgrad Med J"},{"key":"919_CR24","first-page":"760","volume":"71","author":"Y Leng","year":"2023","unstructured":"Leng Y, Yu X, Yang Y, Xia Y. Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. J Investig Med Off Publ Am Fed Clin Res. 2023;71:760\u201372.","journal-title":"J Investig Med Off Publ Am Fed Clin Res"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","volume":"166","author":"LM Wilson","year":"2017","unstructured":"Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med. 2017;166:649\u201358.","journal-title":"Ann Intern Med"},{"key":"919_CR26","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen HS, Lloret MJ, Lalayiannis AD, Shroff R, Evenepoel P, European Renal Osteodystrophy (EUROD) initiative of the CKD-MBD working group of the European Renal Association (ERA), and the CKD-MBD and Dialysis working groups of the European Society of Pediatric Nephrology. Ten tips on how to assess bone health in patients with chronic kidney disease. Clin Kidney J. 2024;17:sfae093.","DOI":"10.1093\/ckj\/sfae093"},{"key":"919_CR27","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s00198-021-05975-7","volume":"32","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust M-H, et al. Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2021;32:2397\u2013405.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR28","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945\u201353.","journal-title":"Kidney Int"},{"key":"919_CR29","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00198-023-06886-5","volume":"34","author":"E Elkhouli","year":"2023","unstructured":"Elkhouli E, Nagy E, Santos CGS, Barreto FC, Chaer J, Jorgetti V, et al. Mixed uremic osteodystrophy: an ill-described common bone pathology in patients with chronic kidney disease. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2023;34:2003\u201312.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR30","first-page":"135","volume":"1","author":"VM Brandenburg","year":"2008","unstructured":"Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. NDT Plus. 2008;1:135\u201347.","journal-title":"NDT Plus"},{"key":"919_CR31","first-page":"e20240023","volume":"46","author":"RB de Oliveira","year":"2024","unstructured":"de Oliveira RB, Carvalho AB, Jorgetti V. Bone aluminum accumulation in the current era. J Bras Nefrol. 2024;46:e20240023.","journal-title":"J Bras Nefrol"},{"key":"919_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/TP.0000000000003226","volume":"105","author":"CG Sotomayor","year":"2021","unstructured":"Sotomayor CG, Benjamens S, Gomes-Neto AW, Pol RA, Groothof D, Te Velde-Keyzer CA, et al. Bone mineral density and aortic calcification: Evidence for a Bone-vascular axis after kidney transplantation. Transplantation. 2021;105:231\u20139.","journal-title":"Transplantation"},{"key":"919_CR33","first-page":"326","volume":"49","author":"SY Ahn","year":"2024","unstructured":"Ahn SY, Ko GJ, Hwang HS, Jeong KH, Jin K, Kim YG, et al. Understanding the Korean dialysis cohort for mineral, vascular calcification, and fracture (ORCHESTRA) study: design, method, and baseline characteristics. Kidney Blood Press Res. 2024;49:326\u201335.","journal-title":"Kidney Blood Press Res"},{"key":"919_CR34","doi-asserted-by":"crossref","unstructured":"Schousboe JT, Lewis JR, Monchka BA, Reid SB, Davidson MJ, Kimelman D, et al. Simultaneous automated ascertainment of prevalent vertebral fracture and abdominal aortic calcification in clinical practice: role in fracture risk assessment. J Bone Miner Res Off J Am Soc Bone Miner Res. 2024;zjae066.","DOI":"10.1093\/jbmr\/zjae066"},{"key":"919_CR35","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.numecd.2024.01.031","volume":"34","author":"R Wei","year":"2024","unstructured":"Wei R, Zhang Y, Huang M, Piao H, Gu Z, Zhu C. Associations between bone mineral density and abdominal aortic calcification: Results of a nationwide survey. Nutr Metab Cardiovasc Dis NMCD. 2024;34:1488\u201395.","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"919_CR36","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgad459","volume":"109","author":"P Szulc","year":"2023","unstructured":"Szulc P, Lewis JR, Chapurlat R. Accelerated bone loss in older men with severe abdominal aortic calcification-the prospective MINOS Study. J Clin Endocrinol Metab. 2023;109:e32\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR37","doi-asserted-by":"publisher","first-page":"101641","DOI":"10.1016\/j.bonr.2022.101641","volume":"17","author":"G Eknoyan","year":"2022","unstructured":"Eknoyan G, Moe SM. Renal osteodystrophy: A historical review of its origins and conceptual evolution. Bone Rep. 2022;17:101641.","journal-title":"Bone Rep"},{"key":"919_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11914-017-0364-1","volume":"15","author":"SM Moe","year":"2017","unstructured":"Moe SM. Renal Osteodystrophy or kidney-induced osteoporosis? Curr Osteoporos Rep. 2017;15:194\u20137.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR39","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/nu14091742","volume":"14","author":"M Fusaro","year":"2022","unstructured":"Fusaro M, Re Sart\u00f2 GV, Gallieni M, Cosmai L, Messa P, Rossini M, et al. Time for revival of bone biopsy with Histomorphometric analysis in chronic kidney disease (CKD): moving from skepticism to pragmatism. Nutrients. 2022;14:1742.","journal-title":"Nutrients"},{"key":"919_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40620-017-0424-8","volume":"30","author":"P Evenepoel","year":"2017","unstructured":"Evenepoel P, Behets GJS, Laurent MR, D\u2019Haese PC. Update on the role of bone biopsy in the management of patients with CKD-MBD. J Nephrol. 2017;30:645\u201352.","journal-title":"J Nephrol"},{"key":"919_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.kint.2022.04.030","volume":"102","author":"HS J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen HS, Ferreira AC, D\u2019Haese P, Haarhaus M, Vervloet M, Lafage-Proust M-H, et al. Bone histomorphometry for the diagnosis of renal osteodystrophy: a call for harmonization of reference ranges. Kidney Int. 2022;102:431\u20134.","journal-title":"Kidney Int"},{"key":"919_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","volume":"95","author":"RH Whitlock","year":"2019","unstructured":"Whitlock RH, Leslie WD, Shaw J, Rigatto C, Thorlacius L, Komenda P, et al. The fracture risk assessment tool (FRAX\u00ae) predicts fracture risk in patients with chronic kidney disease. Kidney Int. 2019;95:447\u201354.","journal-title":"Kidney Int"},{"key":"919_CR43","doi-asserted-by":"publisher","first-page":"e0251912","DOI":"10.1371\/journal.pone.0251912","volume":"16","author":"M Hori","year":"2021","unstructured":"Hori M, Yasuda K, Takahashi H, Yamazaki C, Morozumi K, Maruyama S. Impact of serum magnesium and bone mineral density on systemic fractures in chronic hemodialysis patients. PLoS ONE. 2021;16:e0251912.","journal-title":"PLoS ONE"},{"key":"919_CR44","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.kint.2020.02.035","volume":"98","author":"Y Nakagawa","year":"2020","unstructured":"Nakagawa Y, Komaba H, Hamano N, Wada T, Hida M, Suga T, et al. Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis. Kidney Int. 2020;98:970\u20138.","journal-title":"Kidney Int"},{"key":"919_CR45","doi-asserted-by":"publisher","first-page":"e2903","DOI":"10.1210\/clinem\/dgaa317","volume":"105","author":"JM Hughes-Austin","year":"2020","unstructured":"Hughes-Austin JM, Katz R, Semba RD, Kritchevsky SB, Bauer DC, Sarnak MJ, et al. Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab. 2020;105:e2903-2911.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR46","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.kint.2018.12.024","volume":"95","author":"P Evenepoel","year":"2019","unstructured":"Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, et al. Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int. 2019;95:1461\u201370.","journal-title":"Kidney Int"},{"key":"919_CR47","doi-asserted-by":"publisher","first-page":"116482","DOI":"10.1016\/j.bone.2022.116482","volume":"162","author":"HS J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen HS, Borghs H, Heye S, Smout D, Claes K, Evenepoel P. Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease. Bone. 2022;162:116482.","journal-title":"Bone"},{"key":"919_CR48","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/jcm13041010","volume":"13","author":"MJ Lloret","year":"2024","unstructured":"Lloret MJ, Fusaro M, J\u00f8rgensen HS, Haarhaus M, Gifre L, Alfieri CM, et al. Evaluating osteoporosis in chronic kidney disease: both bone quantity and quality matter. J Clin Med. 2024;13:1010.","journal-title":"J Clin Med"},{"key":"919_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bone.2015.07.015","volume":"81","author":"Y Iwasaki","year":"2015","unstructured":"Iwasaki Y, Kazama JJ, Yamato H, Matsugaki A, Nakano T, Fukagawa M. Altered material properties are responsible for bone fragility in rats with chronic kidney injury. Bone. 2015;81:247\u201354.","journal-title":"Bone"},{"key":"919_CR50","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/jbmr.4574","volume":"37","author":"JG Damrath","year":"2022","unstructured":"Damrath JG, Moe SM, Wallace JM. Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37:1297\u2013306.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR51","doi-asserted-by":"publisher","first-page":"117415","DOI":"10.1016\/j.bone.2025.117415","volume":"194","author":"R Kohler","year":"2025","unstructured":"Kohler R, Segvich DM, Reul O, Metzger CE, Allen MR, Wallace JM. Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease. Bone. 2025;194:117415.","journal-title":"Bone"},{"key":"919_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","volume":"107","author":"M Ketteler","year":"2025","unstructured":"Ketteler M, Evenepoel P, Holden RM, Isakova T, J\u00f8rgensen HS, Komaba H, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;107:405\u201323.","journal-title":"Kidney Int"},{"key":"919_CR53","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.3390\/jcm13082430","volume":"13","author":"D De Mauro","year":"2024","unstructured":"De Mauro D, De Luca G, Marino S, Smakaj A, Rovere G, Liuzza F, et al. Fragility fractures in end-stage chronic kidney disease (CKD) population: patient-related and CKD-Related factor analysis-a single-center experience. J Clin Med. 2024;13:2430.","journal-title":"J Clin Med"},{"key":"919_CR54","doi-asserted-by":"publisher","first-page":"908727","DOI":"10.3389\/fendo.2022.908727","volume":"13","author":"MR Laurent","year":"2022","unstructured":"Laurent MR, Goemaere S, Verroken C, Bergmann P, Body J-J, Bruy\u00e8re O, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the Belgian bone club. Front Endocrinol. 2022;13:908727.","journal-title":"Front Endocrinol"},{"key":"919_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.maturitas.2020.05.006","volume":"139","author":"D Sanchez-Rodriguez","year":"2020","unstructured":"Sanchez-Rodriguez D, Bergmann P, Body JJ, Cavalier E, Gielen E, Goemaere S, et al. The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women. Maturitas. 2020;139:69\u201389.","journal-title":"Maturitas"},{"key":"919_CR56","doi-asserted-by":"publisher","first-page":"155638","DOI":"10.1016\/j.metabol.2023.155638","volume":"145","author":"E Gielen","year":"2023","unstructured":"Gielen E, Dupont J, Dejaeger M, Laurent MR. Sarcopenia, osteoporosis and frailty. Metabolism. 2023;145:155638.","journal-title":"Metabolism"},{"key":"919_CR57","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1111\/nep.70018","volume":"30","author":"MT Do","year":"2025","unstructured":"Do MT, Nghiem DT, Dang HTV, Nguyen DH, Nguyen TTA, Cao NT, et al. Gender differences in the prevalence and associated factors of sarcopenia among maintenance Haemodialysis patients in Vietnam. Nephrol Carlton Vic. 2025;30:e70018.","journal-title":"Nephrol Carlton Vic"},{"key":"919_CR58","doi-asserted-by":"publisher","first-page":"e0262572","DOI":"10.1371\/journal.pone.0262572","volume":"17","author":"A Rashid","year":"2022","unstructured":"Rashid A, Chaudhary Hauge S, Suetta C, Hansen D. Sarcopenia and risk of osteoporosis, falls and bone fractures in patients with chronic kidney disease: A systematic review. PLoS ONE. 2022;17:e0262572.","journal-title":"PLoS ONE"},{"key":"919_CR59","doi-asserted-by":"publisher","first-page":"n2364","DOI":"10.1136\/bmj.n2364","volume":"375","author":"S Iuliano","year":"2021","unstructured":"Iuliano S, Poon S, Robbins J, Bui M, Wang X, De Groot L, et al. Effect of dietary sources of calcium and protein on hip fractures and falls in older adults in residential care: cluster randomised controlled trial. BMJ. 2021;375:n2364.","journal-title":"BMJ"},{"key":"919_CR60","doi-asserted-by":"publisher","first-page":"672971","DOI":"10.3389\/fnut.2021.672971","volume":"8","author":"L Dedeyne","year":"2021","unstructured":"Dedeyne L, Dupont J, Verschueren S, Koppo K, Tournoy J, Matthys C, et al. Personalized protein supplementation improves total protein, leucine, and energy intake in (Pre)Sarcopenic community-dwelling older adults in the ENHANce RCT. Front Nutr. 2021;8:672971.","journal-title":"Front Nutr"},{"key":"919_CR61","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","volume":"191","author":"J Paccou","year":"2024","unstructured":"Paccou J, Yavropoulou MP, Naciu AM, Chandran M, Messina OD, Rolvien T, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. Eur J Endocrinol. 2024;191:G1-17.","journal-title":"Eur J Endocrinol"},{"key":"919_CR62","doi-asserted-by":"crossref","unstructured":"Obeid W, Hiremath S, Topf JM. Protein Restriction for CKD: Time to Move On. Kidney360. 2022;3:1611\u20135.","DOI":"10.34067\/KID.0001002022"},{"key":"919_CR63","doi-asserted-by":"publisher","first-page":"e2426577","DOI":"10.1001\/jamanetworkopen.2024.26577","volume":"7","author":"A Carballo-Casla","year":"2024","unstructured":"Carballo-Casla A, Avesani CM, Beridze G, Ortol\u00e1 R, Garc\u00eda-Esquinas E, Lopez-Garcia E, et al. Protein intake and mortality in older adults with chronic kidney disease. JAMA Netw Open. 2024;7:e2426577.","journal-title":"JAMA Netw Open"},{"key":"919_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00198-019-05190-5","volume":"31","author":"NA Goto","year":"2020","unstructured":"Goto NA, Weststrate ACG, Oosterlaan FM, Verhaar MC, Willems HC, Emmelot-Vonk MH, et al. The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2020;31:13\u201329.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR65","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/ki.2013.547","volume":"86","author":"KL Naylor","year":"2014","unstructured":"Naylor KL, McArthur E, Leslie WD, Fraser L-A, Jamal SA, Cadarette SM, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86:810\u20138.","journal-title":"Kidney Int"},{"key":"919_CR66","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3109\/0886022X.2015.1057459","volume":"37","author":"M Ra\u010di\u0107","year":"2015","unstructured":"Ra\u010di\u0107 M, Petkovi\u0107 N, Bogi\u0107evi\u0107 K, Mari\u0107 I, Matovi\u0107 J, Pejovi\u0107 V, et al. Comprehensive geriatric assessment: comparison of elderly hemodialysis patients and primary care patients. Ren Fail. 2015;37:1126\u201331.","journal-title":"Ren Fail"},{"key":"919_CR67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jama.2024.4166","volume":"332","author":"JM Guirguis-Blake","year":"2024","unstructured":"Guirguis-Blake JM, Perdue LA, Coppola EL, Bean SI. Interventions to prevent falls in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2024;332:58\u201369.","journal-title":"JAMA"},{"key":"919_CR68","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12882-023-03408-7","volume":"24","author":"L Gute","year":"2023","unstructured":"Gute L, Zimbudzi E. Interventions to reduce falls among dialysis patients: a systematic review. BMC Nephrol. 2023;24:382.","journal-title":"BMC Nephrol"},{"key":"919_CR69","doi-asserted-by":"crossref","unstructured":"Hoffmann I, Shojaa M, Kohl M, von Stengel S, Becker C, Gosch M, et al. Exercise Reduces the Number of Overall and Major Osteoporotic Fractures in Adults. Does Supervision Make a Difference? Systematic Review and Meta-Analysis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37:2132\u201348.","DOI":"10.1002\/jbmr.4683"},{"key":"919_CR70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.3284","volume":"33","author":"SL Watson","year":"2018","unstructured":"Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-Intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: The LIFTMOR randomized controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2018;33:211\u201320.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR71","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4008","volume":"35","author":"AT Harding","year":"2020","unstructured":"Harding AT, Weeks BK, Lambert C, Watson SL, Weis LJ, Beck BR. A Comparison of Bone-Targeted Exercise Strategies to Reduce Fracture Risk in Middle-Aged and Older Men with Osteopenia and Osteoporosis: LIFTMOR-M Semi-Randomized Controlled Trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2020;35:1404\u201314.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR72","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/jbmr.4334","volume":"36","author":"M Kistler-Fischbacher","year":"2021","unstructured":"Kistler-Fischbacher M, Yong JS, Weeks BK, Beck BR. A comparison of bone-targeted exercise with and without antiresorptive bone medication to reduce indices of fracture risk in postmenopausal women with low bone mass: The MEDEX-OP randomized controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2021;36:1680\u201393.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR73","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12882-020-01999-z","volume":"21","author":"DF Cardoso","year":"2020","unstructured":"Cardoso DF, Marques EA, Leal DV, Ferreira A, Baker LA, Smith AC, et al. Impact of physical activity and exercise on bone health in patients with chronic kidney disease: a systematic review of observational and experimental studies. BMC Nephrol. 2020;21:334.","journal-title":"BMC Nephrol"},{"key":"919_CR74","doi-asserted-by":"publisher","first-page":"112030","DOI":"10.1016\/j.exger.2022.112030","volume":"171","author":"TB de Ara\u00fajo","year":"2023","unstructured":"de Ara\u00fajo TB, de Luca CH, de Deus LA, Neves RVP, Reis AL, Honorato FS, et al. The effects of home-based progressive resistance training in chronic kidney disease patients. Exp Gerontol. 2023;171:112030.","journal-title":"Exp Gerontol"},{"issue":"130","key":"919_CR75","first-page":"508","volume":"2021","author":"RVP Neves","year":"1985","unstructured":"Neves RVP, Corr\u00eaa HL, Deus LA, Reis AL, Souza MK, Sim\u00f5es HG, et al. Dynamic not isometric training blunts osteo-renal disease and improves the sclerostin\/FGF23\/Klotho axis in maintenance hemodialysis patients: a randomized clinical trial. J Appl Physiol Bethesda Md. 1985;2021(130):508\u201316.","journal-title":"J Appl Physiol Bethesda Md"},{"key":"919_CR76","doi-asserted-by":"crossref","unstructured":"Magalh\u00e3es de Castro B, Dos Santos Rosa T, de Ara\u00fajo TB, de Luca Corr\u00eaa H, de Deus LA, Neves RVP, et al. Effects of cluster set resistance training on bone mineral density and markers of bone metabolism in older hemodialysis subjects: A pilot study. Bone. 2024;189:117240.","DOI":"10.1016\/j.bone.2024.117240"},{"key":"919_CR77","doi-asserted-by":"crossref","unstructured":"Petrauskiene V, Hellberg M, Svensson P, Zhou Y, Clyne N. Bone mineral density after exercise training in patients with chronic kidney disease stages 3 to 5: a sub-study of RENEXC-a randomized controlled trial. Clin Kidney J. 2024;17:sfad287.","DOI":"10.1093\/ckj\/sfad287"},{"key":"919_CR78","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12882-021-02289-y","volume":"22","author":"K Watanabe","year":"2021","unstructured":"Watanabe K, Kamijo Y, Yanagi M, Ishibashi Y, Harada T, Kohzuki M. Home-based exercise and bone mineral density in peritoneal dialysis patients: a randomized pilot study. BMC Nephrol. 2021;22:98.","journal-title":"BMC Nephrol"},{"key":"919_CR79","doi-asserted-by":"publisher","first-page":"h4580","DOI":"10.1136\/bmj.h4580","volume":"351","author":"MJ Bolland","year":"2015","unstructured":"Bolland MJ, Leung W, Tai V, Bastin S, Gamble GD, Grey A, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015;351:h4580.","journal-title":"BMJ"},{"key":"919_CR80","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00198-012-2117-4","volume":"24","author":"S Bourke","year":"2013","unstructured":"Bourke S, Bolland MJ, Grey A, Horne AM, Wattie DJ, Wong S, et al. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2013;24:349\u201354.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR81","doi-asserted-by":"publisher","first-page":"d2040","DOI":"10.1136\/bmj.d2040","volume":"342","author":"MJ Bolland","year":"2011","unstructured":"Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women\u2019s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.","journal-title":"BMJ"},{"key":"919_CR82","doi-asserted-by":"publisher","first-page":"428","DOI":"10.7326\/M23-2598","volume":"177","author":"CA Thomson","year":"2024","unstructured":"Thomson CA, Aragaki AK, Prentice RL, Stefanick ML, Manson JE, Wactawski-Wende J, et al. Long-term effect of randomization to calcium and vitamin D supplementation on health in older women\u202f: postintervention follow-up of a randomized clinical trial. Ann Intern Med. 2024;177:428\u201338.","journal-title":"Ann Intern Med"},{"key":"919_CR83","first-page":"618","volume":"39","author":"P Barrera-Baena","year":"2024","unstructured":"Barrera-Baena P, Rodr\u00edguez-Garc\u00eda M, Rodr\u00edguez-Rubio E, Gonz\u00e1lez-Llorente L, Ortiz A, Zoccali C, et al. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2024;39:618\u201326.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"919_CR84","doi-asserted-by":"crossref","unstructured":"Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245\u201352.","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"issue":"7","key":"919_CR85","first-page":"1","volume":"2017","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;2017(7):1\u201359.","journal-title":"Kidney Int Suppl"},{"key":"919_CR86","first-page":"341","volume":"39","author":"P Evenepoel","year":"2024","unstructured":"Evenepoel P, J\u00f8rgensen HS, Bover J, Davenport A, Bacchetta J, Haarhaus M, et al. Recommended calcium intake in adults and children with chronic kidney disease-a European consensus statement. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2024;39:341\u201366.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"919_CR87","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s10157-024-02493-8","volume":"28","author":"K Kato","year":"2024","unstructured":"Kato K, Nakashima A, Morishita M, Ohkido I, Yokoo T. Calcium-based phosphate binders and bone mineral density in patients undergoing hemodialysis: a retrospective cohort study. Clin Exp Nephrol. 2024;28:917\u201324.","journal-title":"Clin Exp Nephrol"},{"key":"919_CR88","doi-asserted-by":"publisher","first-page":"117210","DOI":"10.1016\/j.bone.2024.117210","volume":"188","author":"A Eisenhauer","year":"2024","unstructured":"Eisenhauer A, Hastuti A, Heuser A, Kolevica A, Brandt B, Shroff R, et al. Calcium isotope composition in serum and urine for the assessment of bone mineral balance (BMB) - The Osteolabs post-market follow-up study. Bone. 2024;188:117210.","journal-title":"Bone"},{"key":"919_CR89","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/ki.2012.33","volume":"81","author":"P Evenepoel","year":"2012","unstructured":"Evenepoel P, Viaene L, Meijers B. Calcium balance in chronic kidney disease: walking the tightrope. Kidney Int. 2012;81:1057\u20139.","journal-title":"Kidney Int"},{"key":"919_CR90","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ki.2011.490","volume":"81","author":"DM Spiegel","year":"2012","unstructured":"Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012;81:1116\u201322.","journal-title":"Kidney Int"},{"key":"919_CR91","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/jama.2021.4807","volume":"325","author":"H Ogata","year":"2021","unstructured":"Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: The LANDMARK randomized clinical trial. JAMA. 2021;325:1946\u201354.","journal-title":"JAMA"},{"key":"919_CR92","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40620-021-01065-3","volume":"35","author":"J Phannajit","year":"2022","unstructured":"Phannajit J, Wonghakaeo N, Takkavatakarn K, Asawavichienjinda T, Praditpornsilpa K, Eiam-Ong S, et al. The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials. J Nephrol. 2022;35:473\u201391.","journal-title":"J Nephrol"},{"key":"919_CR93","doi-asserted-by":"crossref","unstructured":"Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8:CD006023.","DOI":"10.1002\/14651858.CD006023.pub3"},{"key":"919_CR94","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1172\/JCI98093","volume":"128","author":"C Martineau","year":"2018","unstructured":"Martineau C, Naja RP, Husseini A, Hamade B, Kaufmann M, Akhouayri O, et al. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2. J Clin Invest. 2018;128:3546\u201357.","journal-title":"J Clin Invest"},{"key":"919_CR95","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen HS, Vervloet M, Cavalier E, Bacchetta J, de Borst MH, Bover J, et al. The role of nutritional vitamin D in CKD-MBD in children and adults with CKD, on dialysis and after kidney transplantation - a European consensus statement. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025;gfae293.","DOI":"10.1093\/ndt\/gfae293"},{"key":"919_CR96","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jbmr.4469","volume":"37","author":"M Tsujita","year":"2022","unstructured":"Tsujita M, Doi Y, Obi Y, Hamano T, Tomosugi T, Futamura K, et al. Cholecalciferol supplementation attenuates bone loss in incident kidney transplant recipients: A prespecified secondary endpoint analysis of a randomized controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37:303\u201311.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR97","doi-asserted-by":"crossref","unstructured":"Yeung W-CG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, et al. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis Off J Natl Kidney Found. 2023;82:543\u201358.","DOI":"10.1053\/j.ajkd.2023.04.003"},{"key":"919_CR98","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/metabo12030266","volume":"12","author":"PA Ure\u00f1a Torres","year":"2022","unstructured":"Ure\u00f1a Torres PA, Souberbielle JC, Solal MC. Bone fragility in chronic kidney disease stage 3 to 5: The use of vitamin D supplementation. Metabolites. 2022;12:266.","journal-title":"Metabolites"},{"key":"919_CR99","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.3390\/nu15133072","volume":"15","author":"NG Pilkey","year":"2023","unstructured":"Pilkey NG, Novosel O, Roy A, Wilson TE, Sharma J, Khan S, et al. Does native vitamin d supplementation have pleiotropic effects in patients with end-stage kidney disease? A systematic review of randomized trials. Nutrients. 2023;15:3072.","journal-title":"Nutrients"},{"key":"919_CR100","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2018.06.031","volume":"72","author":"ML Melamed","year":"2018","unstructured":"Melamed ML, Chonchol M, Guti\u00e9rrez OM, Kalantar-Zadeh K, Kendrick J, Norris K, et al. The role of vitamin D in CKD Stages 3 to 4: report of a scientific workshop sponsored by the national kidney foundation. Am J Kidney Dis Off J Natl Kidney Found. 2018;72:834\u201345.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"919_CR101","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/nu16152388","volume":"16","author":"B Lapauw","year":"2024","unstructured":"Lapauw B, Laurent MR, Rozenberg S, Body J-J, Bruy\u00e8re O, Gielen E, et al. When and how to evaluate vitamin d status? A viewpoint from the belgian bone club. Nutrients. 2024;16:2388.","journal-title":"Nutrients"},{"key":"919_CR102","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","volume":"18","author":"P Khairallah","year":"2023","unstructured":"Khairallah P, Cherasard J, Sung J, Agarwal S, Aponte MA, Bucovsky M, et al. Changes in bone quality after treatment with etelcalcetide. Clin J Am Soc Nephrol CJASN. 2023;18:1456\u201365.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"919_CR103","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11914-023-00782-x","volume":"21","author":"J Bernardor","year":"2023","unstructured":"Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of cinacalcet and etelcalcetide on bone mineral and cardiovascular disease in dialysis patients. Curr Osteoporos Rep. 2023;21:193\u2013204.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR104","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.kint.2020.04.013","volume":"98","author":"HS J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen HS, Cavalier E, Evenepoel P. Clinical evidence of direct bone effects of cinacalcet. Kidney Int. 2020;98:514\u20135.","journal-title":"Kidney Int"},{"key":"919_CR105","doi-asserted-by":"crossref","unstructured":"Wang AY-M, Tang T-K, Yau Y-Y, Lo WK. Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial. Am J Kidney Dis Off J Natl Kidney Found. 2024;83:456\u2013466.e1.","DOI":"10.1053\/j.ajkd.2023.10.007"},{"key":"919_CR106","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","volume":"8","author":"JS Leere","year":"2020","unstructured":"Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020;8:407\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"919_CR107","first-page":"294","volume":"50","author":"I Dudar","year":"2022","unstructured":"Dudar I, Shifris I, Dudar S, Kulish V. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study. Pol Merkur Lek Organ Pol Tow Lek. 2022;50:294\u20138.","journal-title":"Pol Merkur Lek Organ Pol Tow Lek"},{"key":"919_CR108","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","volume":"109","author":"MB Demay","year":"2024","unstructured":"Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109:1907\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR109","first-page":"329","volume":"14","author":"MS Kuchay","year":"2017","unstructured":"Kuchay MS, Bansal B, Mithal A. Pitfalls in interpreting interventional studies for osteoporosis. Clin Cases Miner Bone Metab Off J Ital Soc Osteoporos Miner Metab Skelet Dis. 2017;14:329\u201331.","journal-title":"Clin Cases Miner Bone Metab Off J Ital Soc Osteoporos Miner Metab Skelet Dis"},{"key":"919_CR110","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00198-022-06462-3","volume":"33","author":"M Abdalbary","year":"2022","unstructured":"Abdalbary M, Sobh M, Elnagar S, Elhadedy MA, Elshabrawy N, Abdelsalam M, et al. Management of osteoporosis in patients with chronic kidney disease. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2022;33:2259\u201374.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR111","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5414\/CN110993","volume":"98","author":"HH Malluche","year":"2022","unstructured":"Malluche HH, Davenport DL, Monier-Faugere M-C, Lima F. Treatment of bone loss in CKD5D: Better survival in patients with non-high bone turnover. Clin Nephrol. 2022;98:219\u201328.","journal-title":"Clin Nephrol"},{"key":"919_CR112","doi-asserted-by":"crossref","unstructured":"Steller Wagner Martins C, Jorgetti V, Moys\u00e9s RMA. Time to rethink the use of bone biopsy to prevent fractures in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27:243\u201350.","DOI":"10.1097\/MNH.0000000000000418"},{"key":"919_CR113","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/jbmr\/zjae055","volume":"39","author":"EF Eriksen","year":"2024","unstructured":"Eriksen EF, Boyce RW, Shi Y, Brown JP, Betah D, Libanati C, et al. Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment. J Bone Miner Res Off J Am Soc Bone Miner Res. 2024;39:729\u201336.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR114","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbmr.3309","volume":"33","author":"DW Dempster","year":"2018","unstructured":"Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Remodeling- and modeling-based bone formation with Teriparatide versus Denosumab: A longitudinal analysis from baseline to 3 months in the ava study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2018;33:298\u2013306.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR115","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2016.11.009","volume":"95","author":"JN Tsai","year":"2017","unstructured":"Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone. 2017;95:20\u20135.","journal-title":"Bone"},{"key":"919_CR116","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet Lond Engl. 2015;386:1147\u201355.","journal-title":"Lancet Lond Engl"},{"key":"919_CR117","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412\u201320.","journal-title":"N Engl J Med"},{"key":"919_CR118","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.1038\/s41598-022-12029-3","volume":"12","author":"M Hori","year":"2022","unstructured":"Hori M, Yasuda K, Takahashi H, Kondo C, Shirasawa Y, Ishimaru Y, et al. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients. Sci Rep. 2022;12:7781.","journal-title":"Sci Rep"},{"key":"919_CR119","doi-asserted-by":"publisher","first-page":"117329","DOI":"10.1016\/j.bone.2024.117329","volume":"190","author":"JM Hughes-Austin","year":"2024","unstructured":"Hughes-Austin JM, Pereira RC, Jorgetti VD, Salusky IB, Ix JH. Static histomorphometry parameters can identify bone turnover status in children and adults with chronic kidney disease. Bone. 2024;190:117329.","journal-title":"Bone"},{"key":"919_CR120","doi-asserted-by":"publisher","first-page":"116066","DOI":"10.1016\/j.bone.2021.116066","volume":"152","author":"HS J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen HS, Behets G, Viaene L, Bammens B, Claes K, Meijers B, et al. Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. Bone. 2021;152:116066.","journal-title":"Bone"},{"key":"919_CR121","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","volume":"79","author":"HS J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen HS, Behets G, Viaene L, Bammens B, Claes K, Meijers B, et al. Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis Off J Natl Kidney Found. 2022;79:667-676.e1.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"919_CR122","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MNH.0000000000000992","volume":"33","author":"P Evenepoel","year":"2024","unstructured":"Evenepoel P, J\u00f8rgensen HS. Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease. Curr Opin Nephrol Hypertens. 2024;33:383\u201390.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"919_CR123","doi-asserted-by":"crossref","unstructured":"Carbonara CEM, Barreto J, Roza NAV, Quadros K da S, Reis LMD, Carvalho AB de, et al. Renal osteodystrophy and clinical outcomes: a prospective cohort study. J Bras Nefrol. 2024;46:e20230119.","DOI":"10.1590\/2175-8239-jbn-2023-0119en"},{"key":"919_CR124","doi-asserted-by":"crossref","unstructured":"Haarhaus M, Evenepoel P, European Renal Osteodystrophy (EUROD) workgroup, Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association\u2013European Dialysis and Transplant Association (ERA-EDTA). Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int. 2021;100:546\u201358.","DOI":"10.1016\/j.kint.2021.04.043"},{"key":"919_CR125","doi-asserted-by":"publisher","first-page":"115751","DOI":"10.1016\/j.bone.2020.115751","volume":"142","author":"S Hildebrand","year":"2021","unstructured":"Hildebrand S, Cunningham J. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease? Bone. 2021;142:115751.","journal-title":"Bone"},{"key":"919_CR126","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/sdi.12388","volume":"28","author":"SM Ott","year":"2015","unstructured":"Ott SM. Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease. Semin Dial. 2015;28:363\u20139.","journal-title":"Semin Dial"},{"key":"919_CR127","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, et al. Five years of anti-resorptive activity after a single dose of zoledronate\u2013results from a randomized double-blind placebo-controlled trial. Bone. 2012;50:1389\u201393.","journal-title":"Bone"},{"key":"919_CR128","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00198-014-3019-4","volume":"26","author":"MR McClung","year":"2015","unstructured":"McClung MR. Bisphosphonate therapy: how long is long enough? Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2015;26:1455\u20137.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR129","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M21-2512","volume":"175","author":"KN Hayes","year":"2022","unstructured":"Hayes KN, Brown KA, Cheung AM, Kim SA, Juurlink DN, Cadarette SM. Comparative fracture risk during osteoporosis drug holidays after long-term Risedronate versus alendronate therapy\u202f: A propensity score-matched cohort study. Ann Intern Med. 2022;175:335\u201343.","journal-title":"Ann Intern Med"},{"key":"919_CR130","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383:743\u201353.","journal-title":"N Engl J Med"},{"key":"919_CR131","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11914-017-0361-4","volume":"15","author":"MR Allen","year":"2017","unstructured":"Allen MR, Aref MW. What animal models have taught us about the safety and efficacy of bisphosphonates in chronic Kidney disease. Curr Osteoporos Rep. 2017;15:171\u20137.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR132","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"PD Miller","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28:2049\u201359.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR133","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-021-06160-6","volume":"33","author":"M Schini","year":"2022","unstructured":"Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, et al. Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2022;33:737\u201344.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR134","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00198-022-06427-6","volume":"33","author":"A Sahota","year":"2022","unstructured":"Sahota A, Barbary R, Cameron M, Stewart A-M, Sahota O. Safety of zoledronate in older patients at high risk of fracture with reduced renal function. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2022;33:1823\u20134.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR135","doi-asserted-by":"crossref","unstructured":"de Roij van Zuijdewijn C, van Dorp W, Florquin S, Roelofs J, Verburgh K. Bisphosphonate nephropathy: A case series and review of the literature. Br J Clin Pharmacol. 2021;87:3485\u201391.","DOI":"10.1111\/bcp.14780"},{"key":"919_CR136","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MNH.0000000000000585","volume":"29","author":"MJ Damasiewicz","year":"2020","unstructured":"Damasiewicz MJ, Nickolas TL. Bisphosphonate therapy in CKD: the current state of affairs. Curr Opin Nephrol Hypertens. 2020;29:221\u20136.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"919_CR137","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis Off J Natl Kidney Found. 2010;56:57\u201368.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"919_CR138","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res Off J Am Soc Bone Miner Res. 2005;20:2105\u201315.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR139","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00774-018-0977-1","volume":"37","author":"T Sugimoto","year":"2019","unstructured":"Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan. J Bone Miner Metab. 2019;37:730\u201340.","journal-title":"J Bone Miner Metab"},{"key":"919_CR140","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","volume":"18","author":"T Shigematsu","year":"2017","unstructured":"Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol. 2017;18:66.","journal-title":"BMC Nephrol"},{"key":"919_CR141","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2007;22:503\u20138.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR142","doi-asserted-by":"publisher","first-page":"205435812412835","DOI":"10.1177\/20543581241283523","volume":"11","author":"R Whitlock","year":"2024","unstructured":"Whitlock R, MacDonald K, Tangri N, Walsh M, Collister D. The Efficacy and safety of bisphosphonate therapy for osteopenia\/osteoporosis in patients with chronic kidney disease: a systematic review and individual patient-level meta-analysis of placebo-controlled randomized trials. Can J Kidney Health Dis. 2024;11:20543581241283524.","journal-title":"Can J Kidney Health Dis"},{"key":"919_CR143","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11914-005-0021-y","volume":"3","author":"PD Miller","year":"2005","unstructured":"Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep. 2005;3:5\u201312.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR144","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11914-023-00858-8","volume":"22","author":"C Vachey","year":"2024","unstructured":"Vachey C, Candellier A, Toutain S, Mac-Way F. The bone-vascular axis in Chronic Kidney Disease: from pathophysiology to treatment. Curr Osteoporos Rep. 2024;22:69\u201379.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR145","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","volume":"35","author":"IR Reid","year":"2020","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, et al. Effects of Zoledronate on cancer, cardiac events, and mortality in Osteopenic older women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2020;35:20\u20137.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR146","doi-asserted-by":"publisher","first-page":"e032571","DOI":"10.1161\/JAHA.123.032571","volume":"13","author":"J Geers","year":"2024","unstructured":"Geers J, Bing R, Pawade TA, Doris MK, Daghem M, Fletcher AJ, et al. Effect of denosumab or alendronate on vascular calcification: secondary analysis of SALTIRE2 randomized controlled trial. J Am Heart Assoc. 2024;13:e032571.","journal-title":"J Am Heart Assoc"},{"key":"919_CR147","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5414\/CN111428","volume":"103","author":"KA Borghoff","year":"2025","unstructured":"Borghoff KA, Ounda AE, Swee ML, Girotra S, Shibli-Rahhal AA, Ten Eyck P, et al. Use of bisphosphonates in chronic kidney disease is associated with cardiovascular death. Clin Nephrol. 2025;103:5\u201311.","journal-title":"Clin Nephrol"},{"key":"919_CR148","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12882-024-03460-x","volume":"25","author":"L He","year":"2024","unstructured":"He L, Li Y, Jin J, Cheng M, Bai Y, Xu J. Comparative efficacy of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of vascular calcification in patients with haemodialysis: a systematic review and network meta-analysis. BMC Nephrol. 2024;25:26.","journal-title":"BMC Nephrol"},{"key":"919_CR149","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","volume":"20","author":"AS Kim","year":"2022","unstructured":"Kim AS, Girgis CM, McDonald MM. Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation. Curr Osteoporos Rep. 2022;20:505\u201315.","journal-title":"Curr Osteoporos Rep"},{"key":"919_CR150","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163\u201370.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR151","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26:1829\u201335.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR152","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri K, Watanabe M, Yoshikawa H, Mitsui H, Endo T, Yamamoto Y, et al. Effects of Denosumab and Alendronate on bone health and vascular function in hemodialysis patients: A Randomized, Controlled Trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2019;34:1014\u201324.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR153","doi-asserted-by":"publisher","first-page":"e0309657","DOI":"10.1371\/journal.pone.0309657","volume":"19","author":"A Kobayashi","year":"2024","unstructured":"Kobayashi A, Yaginuma T, Kato K, Nakashima A, Ohkido I, Yokoo T. Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study. PLoS ONE. 2024;19:e0309657.","journal-title":"PLoS ONE"},{"key":"919_CR154","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","volume":"29","author":"C Thongprayoon","year":"2018","unstructured":"Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, et al. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2018;29:1737\u201345.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR155","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/hdi.13098","volume":"27","author":"Z Gu","year":"2023","unstructured":"Gu Z, Yang X, Wang Y, Gao J. Effects of denosumab on bone mineral density and bone metabolism in patients with end-stage renal disease: A systematic review and meta-analysis. Hemodial Int Int Symp Home Hemodial. 2023;27:352\u201363.","journal-title":"Hemodial Int Int Symp Home Hemodial"},{"key":"919_CR156","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","volume":"331","author":"ST Bird","year":"2024","unstructured":"Bird ST, Smith ER, Gelperin K, Jung TH, Thompson A, Kambhampati R, et al. Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA. 2024;331:491\u20139.","journal-title":"JAMA"},{"key":"919_CR157","doi-asserted-by":"crossref","unstructured":"Bird ST, Gelperin K, Smith ER, Jung TH, Lyu H, Thompson A, et al. The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease\u202f: A Target Trial Emulation. Ann Intern Med. 2024;","DOI":"10.7326\/M24-0013"},{"key":"919_CR158","doi-asserted-by":"publisher","first-page":"117045","DOI":"10.1016\/j.bone.2024.117045","volume":"181","author":"AAS Almodares","year":"2024","unstructured":"Almodares AAS, Elder GJ, Abrahamsen B. Sustained hypophosphatemia after denosumab in a patient on hemodialysis. Bone. 2024;181:117045.","journal-title":"Bone"},{"key":"919_CR159","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/jbmr.3821","volume":"34","author":"D Miyaoka","year":"2019","unstructured":"Miyaoka D, Inaba M, Imanishi Y, Hayashi N, Ohara M, Nagata Y, et al. Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients With Normal Kidney Function by Lowering Serum Phosphorus. J Bone Miner Res Off J Am Soc Bone Miner Res. 2019;34:2028\u201335.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR160","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.4804","volume":"38","author":"A Cowan","year":"2023","unstructured":"Cowan A, Jeyakumar N, McArthur E, Fleet JL, Kanagalingam T, Karp I, et al. Hypocalcemia risk of denosumab across the spectrum of kidney disease: a population-based cohort study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2023;38:650\u20138.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR161","doi-asserted-by":"crossref","unstructured":"Sun X, Bolster MB, Leder BZ, Fan W. Dose-specific effects of denosumab on serum calcium levels in patients with osteoporosis and various renal functions. J Clin Endocrinol Metab. 2024;dgae721.","DOI":"10.1210\/clinem\/dgae721"},{"key":"919_CR162","doi-asserted-by":"crossref","unstructured":"Lloret MJ, J\u00f8rgensen HS, Evenepoel P. Denosumab-induced hypocalcemia in patients treated with dialysis: an avoidable complication? Clin Kidney J. 2024;17:sfae048.","DOI":"10.1093\/ckj\/sfae048"},{"key":"919_CR163","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbspin.2019.07.010","volume":"87","author":"J Dupont","year":"2020","unstructured":"Dupont J, Laurent MR, Dedeyne L, Luyten FP, Gielen E, Dejaeger M. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases. Joint Bone Spine. 2020;87:171\u20133.","journal-title":"Joint Bone Spine"},{"key":"919_CR164","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","volume":"18","author":"K Iseri","year":"2023","unstructured":"Iseri K, Mizobuchi M, Winzenrieth R, Humbert L, Saitou T, Kato T, et al. Long-term effect of denosumab on bone disease in patients with CKD. Clin J Am Soc Nephrol CJASN. 2023;18:1195\u2013203.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"919_CR165","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1210\/clinem\/dgz321","volume":"105","author":"H Lyu","year":"2020","unstructured":"Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, et al. Delayed Denosumab injections and bone mineral density response: an electronic health record-based study. J Clin Endocrinol Metab. 2020;105:1435\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR166","doi-asserted-by":"crossref","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body J-J, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020;dgaa756.","DOI":"10.1210\/clinem\/dgaa756"},{"key":"919_CR167","doi-asserted-by":"crossref","unstructured":"Adami G, Pedrollo E, Rossini M, Fassio A, Braga V, Pasetto E, et al. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus. 2024;8:ziae016.","DOI":"10.1093\/jbmrpl\/ziae016"},{"key":"919_CR168","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/CIA.S120175","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging. 2016;11:1653\u20139.","journal-title":"Clin Interv Aging"},{"key":"919_CR169","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","volume":"35","author":"JP Bilezikian","year":"2019","unstructured":"Bilezikian JP, Hattersley G, Mitlak BH, Hu M-Y, Fitzpatrick LA, Dabrowski C, et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Curr Med Res Opin. 2019;35:2097\u2013102.","journal-title":"Curr Med Res Opin"},{"key":"919_CR170","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2007;18:59\u201368.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR171","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","volume":"65","author":"P Palcu","year":"2015","unstructured":"Palcu P, Dion N, Ste-Marie L-G, Goltzman D, Radziunas I, Miller PD, et al. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. Am J Kidney Dis Off J Natl Kidney Found. 2015;65:933\u20136.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"919_CR172","first-page":"146","volume":"24","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Nakazawa D, Nishio S, Ishikawa Y, Makita M, Kusunoki Y, et al. Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2020;24:146\u201353.","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"919_CR173","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, et al. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27:1441\u201350.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR174","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C, Miller PD, Gua\u00f1abens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26:503\u201311.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR175","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jcph.2050","volume":"62","author":"C-P Hsu","year":"2022","unstructured":"Hsu C-P, Maddox J, Block G, Bartley Y, Yu Z. Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J Clin Pharmacol. 2022;62:1132\u201341.","journal-title":"J Clin Pharmacol"},{"key":"919_CR176","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00774-022-01332-8","volume":"40","author":"A Miyauchi","year":"2022","unstructured":"Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab. 2022;40:677\u201387.","journal-title":"J Bone Miner Metab"},{"key":"919_CR177","doi-asserted-by":"publisher","first-page":"101639","DOI":"10.1016\/j.bonr.2022.101639","volume":"17","author":"M Ogata","year":"2022","unstructured":"Ogata M, Ushimaru S, Fujishima R, Sumi H, Shiizaki K, Tominaga N. Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist. Bone Rep. 2022;17:101639.","journal-title":"Bone Rep"},{"key":"919_CR178","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00198-022-06534-4","volume":"33","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Mizobuchi M, Yoshida S, Terado N, Aoki S, Sato N, et al. Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2022;33:2649\u201352.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"919_CR179","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2023","unstructured":"Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N, et al. One-Year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int. 2023;112:34\u201344.","journal-title":"Calcif Tissue Int"},{"key":"919_CR180","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab. 2021;39:1082\u201390.","journal-title":"J Bone Miner Metab"},{"key":"919_CR181","doi-asserted-by":"publisher","first-page":"101774","DOI":"10.1016\/j.bonr.2024.101774","volume":"21","author":"R Kohler","year":"2024","unstructured":"Kohler R, Segvich DM, Reul O, Metzger CE, Allen MR, Wallace JM. Romosozumab rescues impaired bone mass and strength in a murine model of diabetic kidney disease. Bone Rep. 2024;21:101774.","journal-title":"Bone Rep"},{"key":"919_CR182","doi-asserted-by":"crossref","unstructured":"Hartz MC, Johannessen FB, Harsl\u00f8f T, Langdahl BL. The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis. J Clin Endocrinol Metab. 2024;dgae484.","DOI":"10.1210\/clinem\/dgae484"},{"key":"919_CR183","doi-asserted-by":"crossref","unstructured":"Stokar J, Szalat A. Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study. J Clin Endocrinol Metab. 2024;dgae173.","DOI":"10.1210\/clinem\/dgae173"},{"key":"919_CR184","first-page":"408","volume":"34","author":"VM Brandenburg","year":"2019","unstructured":"Brandenburg VM, Verhulst A, Babler A, D\u2019Haese PC, Evenepoel P, Kaesler N. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2019;34:408\u201314.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"919_CR185","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jbmr.4503","volume":"37","author":"A De Mar\u00e9","year":"2022","unstructured":"De Mar\u00e9 A, Opdebeeck B, Neven E, D\u2019Haese PC, Verhulst A. Sclerostin protects against vascular calcification development in Mice. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37:687\u201399.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"919_CR186","doi-asserted-by":"crossref","unstructured":"Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE, MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol JASN. 2008;19:1430\u20138.","DOI":"10.1681\/ASN.2007050555"},{"key":"919_CR187","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","volume":"63","author":"E Hern\u00e1ndez","year":"2003","unstructured":"Hern\u00e1ndez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003;63:2269\u201374.","journal-title":"Kidney Int"},{"key":"919_CR188","first-page":"461","volume":"8","author":"F Haghverdi","year":"2014","unstructured":"Haghverdi F, Farbodara T, Mortaji S, Soltani P, Saidi N. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J Kidney Dis. 2014;8:461\u20136.","journal-title":"Iran J Kidney Dis"},{"key":"919_CR189","doi-asserted-by":"crossref","unstructured":"El Miedany Y, Gadallah NA, Sarhan E, Toth M, Hasab El Naby MM, Elwy M, et al. Consensus Evidence-Based Clinical Practice Recommendations for the Diagnosis and Treat-To-Target Management of Osteoporosis in Chronic Kidney Disease Stages G4-G5D and Post-transplantation: An Initiative of Egyptian Academy of Bone Health. Kidney Dis Basel Switz. 2022;8:392\u2013407.","DOI":"10.1159\/000526492"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00919-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-025-00919-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00919-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:39:58Z","timestamp":1768473598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-025-00919-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":189,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1007\/s11914-025-00919-0","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"16 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Laurent has received consultancy and lecture fees from Alexion, A.M. Pharma, Amgen, AstraZeneca, Galapagos, Kyowa Kirin, Menarini, Orifarm, Pharmanovia, Takeda, Sandoz, UCB and Will Pharma. Dr. Dupont has received consultancy fees and expenses from Daiichi Sankyo and UCB. Dr. Lemahieu has received consultancy fees from Astellas Pharma, Boehringer-Ingelheim and Fresenius Medical. Dr. Jamar has received travel and consultancy fees from Amgen and AstraZeneca. Dr. Mellaerts has no disclosures. Prof. Dejaeger has received research funding from UCB. Prof. Gielen has received consultancy and lecture fees from Amgen, Takeda, UCB. Prof. Evenepoel has received consultancy and lecture fees from Amgen, Fresenius Medical, Vifor, UCB, Takeda, and travel expenses from GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}